10nm Colloidal Gold for Lateral Flow is a highly stable and uniform 10 nm gold nanoparticles can be supplied in a range from 1 OD to 100 OD. The quality and performance of a conjugate is critical to successful lateral flow test manufacturing. Our products are made in Austin TX and produced in a state-of-the-art manufacturing facility that enable rapid turnaround times while ensuring batch to batch consistency and reliability.
Bulk pricing and manufacturing supply contracts available.
Functionally Tested in Lateral Flow
Specifications 1OD 10nm Gold (1L)
Number of particles/mL
2.5- 8.6 x 1012
Gold Concentration (mg/mL)
5.7- 6.0 x 10-2
Molar Concentration (moles/liter)
0.4-1.4 x 10-8
Particle Diameter
10 nm /- 1.5
Other Products
Aspergillus Antigen(Galactomannan) – Rapid Test
Product Info
Document
Product Info
Name of Product
Aspergillus Antigen (Galactomannan) – Rapid Test
Catalog Number
ASP-025
Short Info
This Rapid Test is for the detection of specific Aspergillus Galactomannan Antigen in Serum or Bronchoalveolar Lavage (BAL).
This product is manufactured by GaDia Diagnostics in Switzerland and distributed in Germany exclusively by Milenia Biotec.
Method/Platform
Immunochromatographic Rapid Test
Range/Assay Sensivity
Test Principle
The principle of the test is colloidal gold immunochromatography. If the sample is positive, the antigens in the sample react with the red-colored nanoparticles and form a complex (Antigen – anti-Aspergillus monoclonal antibodies – gold nanoparticles), which was previously pre-dried on the conjugate pad. The mixture then moves upward on the membrane by capillary action. As the sample flows through the test membrane, the binding conjugate complexes migrate. The anti-Aspergillus antibodies present on the membrane (Test Line) capture the colored conjugate complex and a red line will appear.
The cfDNA Purification Kit (Magnetic Beads) was developed for cell free DNA (cfDNA) enrichment by separating genomic DNA contamination from isolated cfDNA samples.
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
Therefore, an additional purification step to enrich cfDNA before downstream methods helps to improve signal from fragments that originate from cancer cells. A proportion of cancer-derived cfDNA fragment signals are below 100 bp and are often not detectable except by qPCR or single-stranded DNA based library preparation for NGS (1, 2, 3). Furthermore only 1% of cancer-derived fragments are found above 400 bp (1, 2). Capture of size-selected fragments between 90-150 bp improved detection of cancer by 2-4 fold (4). Furthermore, TF-bound and protected cfDNA fragments are also being investigated for active cancer-specific signals down to 35-80 bp (5, 6).
This kit uses Dual Solid Phase Reversible Immobilization (SPRI) technology for cfDNA purification. Most Dual SPRI procedures do NOT recover fragments below 100 bp. The kit can be used for the enrichment of cfDNA isolated from liquid biopsies, plasma, serum, and urine. The kit separates cfDNA (50-500 bp) and genomic DNA, and recovers of 90% of the cfDNA without the high molecular weight genomic DNA with high efficiency. Fragments at 500 bp and above may also be retained. Both the 50-500 bp and >500 bp DNA fractions can be used for downstream applications such as single-stranded or double stranded NGS library prep, qPCR, ddPCR, and other methods.
Features
Separation of cfDNA and genomic DNA; Recovery of both types of DNA
Recovery of cfDNA (50-500 bp)
As short as 50 bp can be recovered
Recovery of high molecular weight genomic DNA
Removal of unwanted components and other impurities
Automation friendly
Examples of cfDNA purification. Both cfDNA and genomic DNA can be recovered separately.
The range of recovered small DNA fragments is from 50 to 500 bp. The input DNA are mixtures of sheared small DNA fragments and intact genomic DNA. The ratios of sheared DNA fragments versus genomic DNA are indicated.
Recovery rates of cfDNA and genomic DNA.
Document
Many diagnostic technologies for detection of disease signals in cfDNA begin with isolation and purification of DNA from liquid biopsy that include urine, plasma, cerebrospinal fluid. The most widely explored biotechnology is assays used to detect cancer-derived plasma cfDNA. Silica-based magnetic bead cfDNA isolation kits can reliably extract total DNA from plasma, but typically yield a large variation in cfDNA that includes the presence of genomic DNA that often depends on tumor stage, tumor size, or healthy status individuals. Most of the commercial cfDNA isolation kits can’t specifically recover the cfDNA while leaving the high molecular weight genomic DNA behind. The presence of genomic DNA can lead to decreased sensitivity or inconsistent results in downstream applications such as next-generation sequencing (NGS), PCR, QPCR, and digital PCR etc.
